Illumina Introduces TruSeq® Stranded mRNA and Total RNA Sequencing Sample Preparation Solutions
Delivers Superior Data Quality for Challenging Samples, Unprecedented View of the Transcriptome
SAN DIEGO--(BUSINESS WIRE)-- Illumina (ILMN) today introduced TruSeq Stranded mRNA and Total RNA Sample Preparation Kits for RNA sequencing. The new reagent kits enable researchers to quickly and easily conduct gene expression studies that provide a complete view of the transcriptome, even from low-quality RNA samples, such as formalin-fixed, paraffin-embedded (FFPE) samples.
The Total RNA Sample Preparation Kit efficiently removes ribosomal RNA and other high abundance transcripts using Epicentres proven Ribo-Zero" ribosomal RNA reduction chemistry, with an improved workflow optimized for high-throughput studies. The resulting combination of high-quality ribosomal removal and sample preparation chemistries into a single, streamlined solution provides an exciting new opportunity for researchers to conduct highly-accurate gene expression studies.
TruSeq Stranded mRNA and Total RNA Sample Preparation Kits offer powerful, high-throughput, and easy-to-use reagent solutions suited to a broad range of study designs, including those that use challenging but important FFPE samples, said Christian Henry, Senior Vice President and General Manager of Illuminas Genomic Solutions Business. These types of samples are a rich source of information on changes in gene expression and regulation associated with cancer and a wide range of other diseases.
The TruSeq Stranded RNA Sample Preparation Kits are available in multiple configurations to suit a wide range of study design needs, with offerings for both mRNA-focused and whole-transcriptome analysis, as well as for both small and large sample sizes. Configurations compatible with human, mouse and rat samples are currently available, with additional offerings planned later this year for plant samples and for the effective removal of globin transcripts from blood samples.
Illuminas new RNA sequencing kits allow researchers to quickly and robustly analyze nearly every aspect of the transcriptome and will certainly be a powerful new tool in unraveling the complexities of gene regulation, said Brenton Graveley, professor at University of Connecticut Health Centre and researcher in the modENCODE Project. We were able to reliably detect expression changes in coding as well as non-coding RNA species, for which important regulatory roles impacting a rapidly broadening array of phenotypes continue to be discovered.
The TruSeq Stranded mRNA and Total RNA Sample Preparation Kits are the newest additions to the TruSeq line of sample prep solutions, which are designed to further advance data quality, ease-of-use, and the cost effectiveness of sequencing. Additional benefits of TruSeq Stranded mRNA and Total RNA Sample Preparation Kits include:
- An improved workflow, requiring less hands-on time while delivering the same high standard of performance and affordability as Illuminas current TruSeq products.
- High strand specificity and uniform coverage in a comprehensive end-to-end solution.
- Availability in multiple configurations, including 48-sample low-throughput kits containing 12 of 24 total available indexes, and 96-sample high-throughput kits. Additionally, the company recently introduced TruSeq DNA HT Sample Preparation Kits, which contain 96 unique index pairs pre-loaded into 96-well plates.
TruSeq Stranded mRNA and Total RNA Sample Preparation Kits are now shipping. For more information, visit www.illumina.com/RNA.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: IlluminaCopyright Business Wire 2012